S(+)ibuprofen proposed labeling identical to existing ibuprofen products.
This article was originally published in The Tan Sheet
Executive Summary
BAYER S(+)IBUPROFEN PROPOSED LABELING IDENTICAL TO IBUPROFEN product labeling on the market, the firm told an Oct. 9 joint meeting of the FDA Nonprescription Drugs and Arthritis Drugs Advisory Committees in Bethesda, Md. Bayer plans to use the "Drug Facts" format for S(+)ibuprofen (dexibuprofen) labeling, with the same directions and warnings as existing ibuprofen products. The package also would contain a consumer education leaflet and display a toll-free number for inquiries. The committee voted not to recommend approval for the NDA for dexibuprofen OTC marketing.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning